Current stock page

Stock Analysis

Tarsus Pharmaceuticals, Inc. (TARS) Stock Analysis

Tarsus Pharmaceuticals, Inc. (TARS) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

TARS Stock Analysis Summary

Tarsus Pharmaceuticals, Inc. (TARS) currently has an AIQ Score of 65/100, indicating a bullish setup. Momentum is the strongest factor at 76/100. Quality is the weakest current factor at 50/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

TARS at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$80.28
AIQ Score65/100
Overall ViewBullish
Technical Analysis ConsensusStrong Buy
Market Cap$3.73B
P/E Ratio (TTM)-5.29
Forward P/E—
EPS (Q3 FY2026)-$14.40
Revenue (Q3 FY2026)$194.57M
Dividend Yield (TTM)0.00%
Beta0.56
Volume732.09K
52-week range$53.89-$91.53
RSI 1464.82
50-Day SMA$74.85
200-Day SMA$67.97
Analyst Price Target$109.25
Next EarningsFeb 22, 2027
As of Nov 13, 2026 · Market close

TARSTarsus Pharmaceuticals, Inc.

Healthcare / Biotechnology

Leader

Strong Relative Position

BullishEdge 8/10
$80.28+$3.39 (+4.41%)

Latest quote

  • Momentum
    76
  • Value
    75
  • Quality
    50
  • Risk resilience
    59
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

TARS Stock Analysis Summary

Tarsus Pharmaceuticals, Inc. (TARS) currently has an AIQ Score of 65/100, indicating a bullish setup. Momentum is the strongest factor at 76/100. Quality is the weakest current factor at 50/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bullish

In a bullish regime, TARS has AIQ Score of 65/100 with Momentum base of 76/100 and fading Quality at 50/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (76/100) leads while Quality (50/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · 4.41% stock move · TARS classified in Biotechnology.

Current Evidence

BullishTARS is in a bullish AIQ regime; Momentum is the strongest visible factor at 76/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is TARS Bullish or Bearish Right Now?

TARS currently has a bullish overall setup. Momentum is the strongest factor at 76/100, while Quality is weakest at 50/100. The current evidence suggests a constructive setup.

Bull Case
  • - Momentum is constructive at 76/100.
  • - Price is +7.26% above its 50-day SMA.
  • - Analyst target implies +36.09% upside from the latest quote.
  • - Technical consensus has more buy votes than sell votes (37 vs 6).
Bear Case
  • - No strong bearish evidence is available in the current snapshot.

Current Consensus

TARS's Technical Analysis Consensus is currently Strong Buy, with 37 buy, 3 neutral, and 6 sell votes. TARS's 14-day RSI is 64.82, which places the stock in a constructive momentum range. TARS's beta is 0.56, indicating lower market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in TARS?

The largest recent change in TARS is Momentum moving down by 2.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
+0.0
Momentum
-2.0
Quality
+0.0
Risk
+1.0

What Would Change the TARS Outlook?

The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

TARS Decision Framework

Public evidence layers, setup checks, and risk context for Tarsus Pharmaceuticals, Inc..

Tarsus Pharmaceuticals, Inc. (TARS) Stock Analysis

Tarsus Pharmaceuticals, Inc. has an AIQ Score of 65/100 in a Bullish regime. Momentum is strongest at 76/100. Beta is 0.56, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextTARS is in a Bullish AIQ regime with score 65/100.
Signal ConflictThe primary conflict is that momentum leads at 76/100 while quality lags at 50/100.
Factor EvidenceMomentum 76/100 · Value 75/100 · Quality 50/100 · Risk 59/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Momentum is the strongest factor at 76/100.

TimingPass

Momentum is 76/100 and RSI (14) is 64.8.

Regime fitPass

TARS is in a Bullish regime at 65/100.

Risk controlWait

Risk factor is 59/100 with beta 0.56 and annual volatility 45.02%.

ConflictWait

Current conflict: momentum leads at 76/100 while quality lags at 50/100.

AIQ Score
65/100
Price
$80.28
Beta
0.56
RSI (14)
64.8

TARS Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

TARS Fundamentals

TARS valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$194.57M
Net income
-$668.33M
Free cash flow
-$7.22M
View full TARS fundamental analysis

TARS Technical Analysis

TARS technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Buy
RSI 14
64.82
Price vs SMA-50
+7.26%
View full TARS technical analysis

TARS Stock Catalysts

Track TARS earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 22, 2027
Analyst target
$109.25
News items
4
View TARS earnings and stock catalysts

TARS Dividend Analysis

TARS dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View TARS dividend history and analysis

TARS Financial Data

TARS revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$194.57M
EPS
-$14.40
Periods
8
View TARS financials

TARS Risk Analysis

TARS volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.56
Risk score
59/100
1Y volatility
45.02%
View TARS risk analysis

TARS Stock News

TARS stock news, market tone, recent headlines, and catalyst context.

News items
4
Updated
Nov 15, 2026
Sentiment
—
Read TARS stock news

TARS vs Biotechnology Peers

Current peer cohort: TARS · TGTX · TNGX · TRVI · TSHA. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
TARS
Current stock
65/10075/10076/10059/1000.3645.02%Current
TGTX
TG Therapeutics, Inc.
76/10065/10093/10063/1001.7446.06%TARS vs TGTX
TNGX
Tango Therapeutics, Inc.
61/100—60/10038/1001.61101.07%TARS vs TNGX
TRVI
Trevi Therapeutics, Inc.
63/100—52/10051/1000.5259.27%TARS vs TRVI
TSHA
Taysha Gene Therapies, Inc.
35/100—32/10037/1000.3270.69%TARS vs TSHA
Pairwise Compare links: TGTX · TNGX · TRVI · TSHATARS vs TGTXTARS vs TNGXTARS vs TRVITARS vs TSHACompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a TARS stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for TARS: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-5.29
As of Nov 13, 2026
Revenue growth
63.92%
Gross margin
93.21%
Current debt / equity
0.85
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$194.57M
Quarter net income
-$668.33M
Quarter free cash flow
-$7.22M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bullish
Momentum
Bullish
RSI 14
64.82
MACD
0.81

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
59/100
Beta
0.56
Annual volatility
45.02%
Max drawdown
-32.00%

TARS Stock FAQ

What is TARS stock price today?

Tarsus Pharmaceuticals, Inc.'s current stock price is $80.28. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is TARS bullish or bearish right now?

TARS's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is TARS's market cap?

TARS's market cap is $3.73B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is TARS's current P/E ratio?

TARS's current P/E ratio is -5.29 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is TARS's RSI?

TARS's 14-day RSI is 64.82 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is TARS above its 50-day and 200-day moving averages?

TARS is 7.26% from its 50-day SMA and 18.11% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is TARS's next earnings date?

TARS's next earnings date is currently listed as Feb 22, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does TARS pay a dividend?

TARS's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.